ClinicalTrials.gg
CompletedNCT02665637Updated Aug 26, 2016

Study Comparing Pharmacokinetics, Safety and Immunogenicity of CT-P6 and US-licensed Herceptin

A Phase 1 interventional study of Trastuzumab in Healthy Volunteers, sponsored by Celltrion. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-08-26.

Sponsored by Celltrion · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This is a double-blind, two-arm, parallel-group, single-dose study.

Read the detailed description

This is a double-blind, two-arm, parallel-group, single-dose study. A total of 70 healthy male subjects will be enrolled.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Celltrion is the lead sponsor of 77 studies on the registry; 2 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 14 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male subject
  2. Subject voluntarily agrees to participate in this study

Exclusion criteria

Exclusion Criteria:

  1. Female.
  2. Subject has a medical condition of disease including one or more.
  3. Smoker
05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
70 participants (actual)

Study arms

  • Active comparator
    CT-P6

    Trastuzumab

    Drug: Trastuzumab

  • Active comparator
    US-licensed Herceptin

    Trastuzumab

    Drug: Trastuzumab

Interventions

  • Each patient may receive single dose by intravenous infusion

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics will be assessed by AUC

    Pharmacokinetics will be assessed by AUC.

    Time frame: up to week 10

07

Study locations

1 site
  • PPD Phase I Clinic
    Austin, Texas 78744, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2015, a primary completion of Apr 2016 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2016
First posted
Jan 28, 2016
Start
Dec 2015
Primary completionActual
Apr 2016
CompletionActual
Apr 2016
Last update
Aug 26, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02665637
Lead sponsor
Celltrion
Responsible party
Sponsor
First posted
Jan 28, 2016
Start date
Dec 2015
Primary completion
Apr 2016
Completion
Apr 2016
Last update
Aug 26, 2016

Study contacts

Rebecca Wood-Horrall, MD
principal investigator · PPD Phase I Clinic

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion